Diabetes therapy: Novel patents targeting the glucose-induced insulin secretion

Recent Patents on DNA and Gene Sequences

Volumn 4, Issue 1, 2010, Pages 1-9

  Polakof, Sergio ^a  

^a UNIVERSITY OF VIGO   (Spain)

Author keywords

Diabetes; GLP 1; Glucokinase; Glucose; Insulin; KATP; Pancreas

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADENOVIRUS VECTOR; AMIDE; ANTIDIABETIC AGENT; COMPLEMENTARY DNA; COMPLEMENTARY RNA; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DNA; ENZYME ACTIVATOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOKINASE ACTIVATOR; GLUCOSE; HETEROCYCLIC COMPOUND; IMIDAZOPYRIDINE DERIVATIVE; INDOLE DERIVATIVE; INSULIN; LIRAGLUTIDE; OXIME DERIVATIVE; POTASSIUM CHANNEL AFFECTING AGENT; PROPIONAMIDE DERIVATIVE; PROTEIN INHIBITOR; RIBOZYME; SMALL INTERFERING DNA; SMALL INTERFERING RNA; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

DIABETES MELLITUS; DRUG EFFECT; GENE SILENCING; GENE THERAPY; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREATITIS; PATENT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; REVIEW; RIBOZYME THERAPY; THYROID TUMOR;

DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; GENE THERAPY; GLUCAGON-LIKE PEPTIDE 1; GLUCOKINASE; GLUCOSE; INSULIN; PATENTS AS TOPIC; SECRETORY RATE;

EID: 77950534968     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221510790410778     Document Type: Review

References (52)

1. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346.
2. Wagman AS, Nuss JM. Current therapies and emerging targets for the treatment of diabetes. Curr Pharm Des 2001; 7: 417-450.
3. Matschinsky FM, Glaser B, Magnuson MA. Pancreatic β-cell glucokinase. Closing the gap between theoretical concepts and experimental realities. Diabetes 1998; 47: 307-315.
4. Prentki M, Tornheim K, Corkey BE. Signal transduction mechanisms in nutrient-induced insulin secretion. Diabetologia 1997; 40 (Suppl 2): S32-S41.
5. Schuit FC, Huypens P, Heimberg H, Pipeleers DG. Glucose sensing in pancreatic β-cells. A model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus. Diabetes 2001; 50: 1-11.
6. Thorens B, Sarkar HK, Kaback HR, Lodish HF. Cloning and functional expression in bacteria of a novel glucose transporter present in liver, intestine, kidney, and beta-pancreatic islet cells. Cell 1988; 55: 281-290.
7. Schuit F, Moens K, Heimberg H, Pipeleers D. Cellular origin of hexokinase in pancreatic islets. J Biol Chem 1999; 274: 32803-32809.
8. Matschinsky FM. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 1996; 45: 223-241.
9. Wollheim CB. Beta-cell mitochondria in the regulation of insulin secretion: a new culprit in type II diabetes. Diabetologia 2000; 43: 265-277.
10. Detimary P, Dejonghe S, Ling Z, Pipeleers D, Schuit F, Henquin JC. The changes in adenine nucleotides measured in glucose-stimulated rodent islets occur in beta cells but not in alpha cells and are also observed in human islets. J Biol Chem 1998; 273: 33905-33908.
11. Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev 1999; 20: 101-135.
12. Tucker SJ, Gribble FM, Proks P, et al. Molecular determinants of KATP channel inhibition by ATP. EMBO J 1998; 17: 3290-3296.
13. Nichols CG, Shyng SL, Nestorowicz A, et al. Adenosine diphosphate as an intracellular regulator of insulin secretion. Science 1996; 272: 1785-1787.
14. Ashcroft FM, Proks P, Smith PA, Ammala C, Bokvist K, Rorsman P. Stimulus-secretion coupling in pancreatic beta cells. J Cell Biochem 1994; 55 (Suppl): 54-65.
15. + channels in mouse B cells. J Clin Invest 1993; 91: 871-880.
16. +-ATP channel-independent pathway of regulation of insulin secretion by glucose: in search of the underlying mechanism. Diabetes 1998; 47: 1713-1721.
17. Farret A, Lugo-Garcia L, Galtier F, Gross R, Petit P. Pharmacological interventions that directly stimulate or modulate insulin secretion from pancreatic beta-cell: implications for the treatment of type 2 diabetes. Fundam Clin Pharmacol 2005; 19: 647-656.
18. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009; 8: 399-416.
19. Matschinsky FM, Magnuson MA, Zelent D, et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 2006; 55: 1-12.
20. Murray, A., Lau, J., Vedso, P., Kristiansen, M., Jeppesen, L.: WO2007006760A1 (2007).
21. Sugawara, K., Matsudaira, T., Sugama, H., Nawano, M., Ohashi, R., Chashi, R.: WO2007007886A1 (2007).
22. Iwata, H., Kohara, Y., Cao, S.X., et al.: WO2007028135A2 (2007).
23. Takahashi, K., Ogino, Y., Nishimura, T.: WO2007037534A1 (2007).
24. Hayakawa, M., Nigawara, T., Tsuchiya, K.: WO2007026761A1 (2007).
25. Hayakawa, M., Nigawara, T., Tsuchiya, K., Nagayoshi, A., Hondo, T.: WO2007043638A1 (2007).
26. Fukuda, Y., Asahina, Y., Takadoi, M.: WO2008111473A1 (2008).
27. Martin, N.G., McKerrecher, D., Pike, K.G., Waring, M.J., Mackerrecher, D., Mc Kerrecher, D.: WO2008050117A1 (2008).
28. Chen, S., Cheng, P.T.W., Smirk, R.A.: WO2008154563A1 (2008).
29. Bhuniya, D., Kapkoti, S.G., Warrier, S.J.: WO2008149382A1 (2008).
30. Cheng, P.T.W., Ryono, D.E., Shi, Y., Wang, Y.: US2009030046A1 (2009).
31. Nichols CG. KATP channels as molecular sensors of cellular metabolism. Nature 2006; 440: 470-476.
32. Proks P, Ashcroft FM. Modeling KATP channel gating and its regulation. Prog Biophys Mol Biol 2009; 99: 7-19.
33. Antel, J., Gregory, P., Lange, J.H.M., et al.: WO2007125048A1 (2007).
34. Castle, N.A., Rigdon, G.C., Krafte, D.S., Castle, N., Rigdon, G., Krafte, D.: US2009036538A1 (2009).
35. Toyoshima, H., Yamada, N., Yokoo, T.: WO2009013794A1 (2009).
36. Toyoshima, H., Yokoo, T., Yamada, N.: JP2007209214A (2007).
37. Agius, L.: WO2006043036A2 (2006).
38. Simpson, A.M., Tao, C.: WO2009021276A1 (2009).
39. Yoon, J., Yoon, C., Han, J., Ji, W.Y.: US2007020237A1 (2007).
40. Perfetti R, Merkel P. Glucagon-like peptide-1: A major regulator of pancreatic beta-cell function. Eur J Endocrinol 2000; 143: 717-725.
41. Gromada J, Brock B, Schmitz O, Rorsman P. Glucagon-like peptide-1: Regulation of insulin secretion and therapeutic potential. Basic Clin Pharmacol Toxicol 2004; 95: 252-262.
42. Lee, S.P., Zhou, P., Buber, M.N.T.: US20080306030 (2008).
43. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept 2005; 128: 117-124.
44. Das, J., Jain, R., Magadi, S.K.: WO2009093269A1 (2009).
45. Dugi, K., Himmelsbach, F., Mark, M.: WO2009022010-A1 (2009).
46. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089.
47. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and betacell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187-1194.
48. De Block CEM, Van Gaal LF. GLP-1 receptor agonists for type 2 diabetes. Lancet 2009; 374: 4-6.
49. Kajihara, Y., Tsuji, T., Sakamoto, I.: WO2008155900A1 (2008).
50. Bachovchin, W.W., Sanford, D.G., Bachovchin, W., Sanford, D.: WO2007030519A2 (2007).
51. Glaesner, W., Mayer, J.P., Millican, R.L.: WO2006124529A1 (2006).
52. Sandoval DA. Obici S, Seeley RJ. Targeting the CNS to treat type 2 diabetes. Nat Rev Drug Discov 2009; 8: 386-398.